Bioventus Inc. revised earnings guidance for the full-year 2024. Based on strong execution and significant momentum across the business, Bioventus is raising financial guidance for full-year 2024. The Company now expects Net sales of $535 million to $550million, an increase of $15 million from previous guidance.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.795 USD | -1.95% | +7.86% | +28.94% |
05-07 | Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 | CI |
05-07 | Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.94% | 442M | |
+75.71% | 12.56B | |
-23.93% | 7.47B | |
+8.28% | 6.75B | |
+11.63% | 5.5B | |
-16.58% | 4.94B | |
+29.47% | 4.66B | |
-25.80% | 3.75B | |
-23.06% | 2.92B | |
-2.23% | 1.98B |
- Stock Market
- Equities
- BVS Stock
- News Bioventus Inc.
- Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024